This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.
-
Working with individual set: THCA-TP
-
Number of patients in set: 401
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:THCA-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 9
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
nnon = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | longname | codelen | nnei | nncd | nsil | nmis | nstp | nspl | nind | nnon | npat | nsite | pCV | pCL | pFN | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 2371 | 59 | 0 | 1 | 236 | 0 | 0 | 4 | 240 | 240 | 6 | 9.6e-15 | 1e-05 | 1e-05 | 1e-16 | 6.1e-13 |
2 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 590 | 34 | 0 | 0 | 34 | 0 | 0 | 0 | 34 | 34 | 2 | 1.3e-16 | 1e-05 | 0.0069 | 1e-16 | 6.1e-13 |
3 | HRAS | v-Ha-ras Harvey rat sarcoma viral oncogene homolog | 659 | 104 | 0 | 0 | 14 | 0 | 0 | 0 | 14 | 14 | 2 | 3.4e-16 | 1e-05 | 0.0037 | 1e-16 | 6.1e-13 |
4 | EIF1AX | eukaryotic translation initiation factor 1A, X-linked | 459 | 175 | 0 | 0 | 4 | 0 | 2 | 0 | 6 | 6 | 5 | 8e-09 | 0.0003 | 0.21 | 6.3e-11 | 2.7e-07 |
5 | NUP93 | nucleoporin 93kDa | 2544 | 111 | 0 | 0 | 1 | 3 | 0 | 0 | 4 | 4 | 2 | 6.8e-09 | 0.0004 | 0.23 | 7.5e-11 | 2.7e-07 |
6 | PPM1D | protein phosphatase 1D magnesium-dependent, delta isoform | 1838 | 267 | 0 | 0 | 1 | 0 | 0 | 4 | 5 | 5 | 5 | 3.8e-09 | 1 | 0.89 | 7.7e-08 | 0.00024 |
7 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 709 | 122 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 4 | 3 | 0.000073 | 0.035 | 0.14 | 0.000018 | 0.047 |
8 | MSLNL | mesothelin-like | 3222 | 67 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 0.00012 | 1 | 0.019 | 0.000039 | 0.089 |
9 | DLC1 | deleted in liver cancer 1 | 4732 | 152 | 0 | 1 | 4 | 0 | 0 | 0 | 4 | 4 | 3 | 0.022 | 0.0045 | 0.0095 | 0.000048 | 0.097 |
10 | ITGAL | integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | 3633 | 37 | 0 | 0 | 3 | 0 | 0 | 1 | 4 | 4 | 4 | 0.000051 | 1 | 0.084 | 0.000068 | 0.12 |
11 | TG | thyroglobulin | 8498 | 137 | 0 | 4 | 6 | 0 | 0 | 5 | 11 | 11 | 11 | 7.7e-06 | 1 | 0.59 | 0.000098 | 0.16 |
12 | NLRP6 | NLR family, pyrin domain containing 6 | 2706 | 132 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 1 | 0.025 | 0.001 | 0.001 | 0.00029 | 0.44 |
13 | HEATR1 | HEAT repeat containing 1 | 6611 | 12 | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 3 | 3 | 0.00013 | 1 | 0.12 | 0.00037 | 0.48 |
14 | ARFGEF2 | ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) | 5510 | 57 | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 4 | 4 | 0.000033 | 1 | 0.94 | 0.00037 | 0.48 |
15 | GBF1 | golgi-specific brefeldin A resistance factor 1 | 5736 | 19 | 0 | 0 | 1 | 0 | 2 | 1 | 4 | 4 | 4 | 0.000047 | 1 | 0.76 | 0.00052 | 0.62 |
16 | OR56A1 | olfactory receptor, family 56, subfamily A, member 1 | 961 | 75 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 0.0051 | 1 | 0.01 | 0.00055 | 0.62 |
17 | ABCD1 | ATP-binding cassette, sub-family D (ALD), member 1 | 2274 | 376 | 0 | 0 | 2 | 1 | 0 | 0 | 3 | 3 | 3 | 0.00058 | NaN | NaN | 0.00058 | 0.62 |
18 | DHX8 | DEAH (Asp-Glu-Ala-His) box polypeptide 8 | 3753 | 131 | 0 | 1 | 2 | 0 | 1 | 0 | 3 | 3 | 3 | 0.000064 | 1 | 0.72 | 0.00068 | 0.69 |
19 | MAS1L | MAS1 oncogene-like | 1135 | 22 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.0069 | 0.01 | 0.47 | 0.00073 | 0.7 |
20 | LMX1B | LIM homeobox transcription factor 1, beta | 1272 | 352 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 1 | 0.0098 | 0.01 | 0.059 | 0.001 | 0.91 |
21 | CREB3L3 | cAMP responsive element binding protein 3-like 3 | 1422 | 50 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 3 | 0.00036 | 1 | 0.2 | 0.0011 | 0.93 |
22 | OR6K6 | olfactory receptor, family 6, subfamily K, member 6 | 1032 | 40 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.011 | 0.01 | 0.86 | 0.0012 | 0.96 |
23 | TRPM4 | transient receptor potential cation channel, subfamily M, member 4 | 3743 | 21 | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 4 | 4 | 0.00013 | 1 | 0.97 | 0.0013 | 1 |
24 | SLC12A4 | solute carrier family 12 (potassium/chloride transporters), member 4 | 3578 | 40 | 0 | 1 | 4 | 0 | 0 | 0 | 4 | 4 | 4 | 0.00073 | 1 | 0.12 | 0.0014 | 1 |
25 | CACNA2D4 | calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 3562 | 30 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 2 | 0.00057 | 1 | 0.24 | 0.0015 | 1 |
26 | POTEE | POTE ankyrin domain family, member E | 3286 | 117 | 0 | 1 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.016 | 0.01 | 0.84 | 0.0016 | 1 |
27 | TBC1D7 | TBC1 domain family, member 7 | 910 | 91 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 2 | 0.0016 | 1 | 0.075 | 0.0016 | 1 |
28 | ATP6V1A | ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A | 1910 | 156 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.017 | 0.01 | 0.91 | 0.0017 | 1 |
29 | TSG101 | tumor susceptibility gene 101 | 1209 | 250 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 0.019 | 0.01 | 0.46 | 0.0018 | 1 |
30 | JMJD1C | jumonji domain containing 1C | 7723 | 1 | 0 | 1 | 0 | 3 | 0 | 1 | 4 | 4 | 4 | 0.00021 | 1 | 0.55 | 0.002 | 1 |
31 | SLC12A5 | solute carrier family 12, (potassium-chloride transporter) member 5 | 3576 | 24 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 2 | 2 | 0.0019 | 1 | 0.05 | 0.002 | 1 |
32 | CHEK2 | CHK2 checkpoint homolog (S. pombe) | 1821 | 365 | 0 | 0 | 4 | 1 | 0 | 0 | 5 | 5 | 5 | 0.00022 | 1 | 0.74 | 0.002 | 1 |
33 | ACBD5 | acyl-Coenzyme A binding domain containing 5 | 1626 | 74 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | 2 | 0.0011 | 1 | 0.1 | 0.0021 | 1 |
34 | USP9X | ubiquitin specific peptidase 9, X-linked | 7885 | 15 | 0 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 0.00023 | 1 | 0.59 | 0.0021 | 1 |
35 | DNASE2 | deoxyribonuclease II, lysosomal | 1103 | 70 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 3 | 0.00045 | 1 | 0.49 | 0.0023 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.